Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.31 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13527625 | 0.96 | ALDH1A1 (0.41) | ALDH1A1RORCKDM4ETGFBR1ACVR1 | |
| SCHEMBL14083227 | 0.88 | HIF1A (0.31) | — | |
| SCHEMBL20026339 | 0.88 | HIF1A (0.33) | ALDH1A1KDM4E | |
| SCHEMBL13527721 | 0.88 | HIF1A (0.33) | ALDH1A1KDM4E | |
| SCHEMBL20026108 | 0.87 | HTT (0.33) | ALDH1A1KDM4E | |
| SCHEMBL13527720 | 0.87 | HTT (0.33) | ALDH1A1KDM4E | |
| SCHEMBL20026123 | 0.83 | PDE4A (0.38) | — | |
| SCHEMBL13527659 | 0.83 | PDE4A (0.38) | — | |
| SCHEMBL14083279 | 0.82 | MAPT (0.34) | ALDH1A1RORCKDM4E | |
| SCHEMBL13527623 | 0.82 | ALDH1A1 (0.37) | ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180094016-A1 | Triazole Compounds And Methods Of Making And Using The Same | BioVersys AG (CH) | 2018-04-05 | — | — | US | disclosed |
| EP-1934238-B1 | TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | MELINTA THERAPEUTICS INC (US) | 2017-06-28 | — | — | EP | disclosed |
| US-20160031926-A1 | Triazole Compounds and Methods of Making and Using the Same | BioVersys AG (CH) | 2016-02-04 | — | — | US | disclosed |
| US-20160031926-A1 | Triazole Compounds and Methods of Making and Using the Same | BioVersys AG (CH) | 2016-02-04 | — | — | US | disclosed |
| US-9006189-B2 | Triazole compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-9006189-B2 | Triazole compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-20140088031-A1 | Triazole Compounds and Methods of Making and Using the Same | RIB-X PHARMACEUTICALS, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-20140088031-A1 | Triazole Compounds and Methods of Making and Using the Same | RIB-X PHARMACEUTICALS, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-20130065845-A1 | Triazole Compounds and Methods of Making and Using the Same | BioVersys AG (CH) | 2013-03-14 | — | — | US | disclosed |
| US-8278281-B2 | Triazole compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-8278281-B2 | Triazole compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-20100016956-A1 | Triazole compounds and methods of making and using the same | BioVersys AG (CH) | 2010-01-21 | — | — | US | disclosed |
| US-20100016956-A1 | Triazole compounds and methods of making and using the same | BioVersys AG (CH) | 2010-01-21 | — | — | US | disclosed |
| WO-2007025284-A1 | TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB-X PHARMACEUTICALS, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016956-A1 | Triazole compounds and methods of making and using the same | IL33, PROKR1, PGC | ALDH1A1 3557/4885RORC 289/4885KDM4E 4210/4885 |
| US-20180094016-A1 | Triazole Compounds And Methods Of Making And Using The Same | IL33, PROKR1, VIP | ALDH1A1 3532/4885RORC 316/4885KDM4E 4532/4885 |
| US-20130065845-A1 | Triazole Compounds and Methods of Making and Using the Same | IL33, PROKR1, VIP | ALDH1A1 3532/4885RORC 316/4885KDM4E 4532/4885 |
| US-20160031926-A1 | Triazole Compounds and Methods of Making and Using the Same | IL33, PROKR1, VIP | ALDH1A1 3532/4885RORC 316/4885KDM4E 4532/4885 |
| US-20140088031-A1 | Triazole Compounds and Methods of Making and Using the Same | IL33, PROKR1, VIP | ALDH1A1 3532/4885RORC 316/4885KDM4E 4532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.